Phase I/II Study Evaluates Zilurgisertib with or Without Ruxolitinib in Myelofibrosis

By Prithviraj Bose, MD, Cecilia Brown - Last Updated: June 7, 2023

Prithviraj Bose, MD, of the University of Texas MD Anderson Cancer Center, discusses results of an ongoing open-label, multicenter, phase I/II study of zilurgisertib alone or with ruxolitinib in myelofibrosis.

Dr. Bose and colleagues presented the research during the 2023 American Society of Clinical Oncology Annual Meeting.

The dose-escalation and dose-expansion study evaluated the safety and activity of zilurgisertib, a selective, oral ALK2 inhibitor, in patients who had myelofibrosis-associated anemia.

Zilurgisertib is “purely for anemia and could serve as a really nice companion or partner for ruxolitinib,” Dr. Bose said.

The study’s primary endpoint is safety and tolerability. Its secondary endpoints include efficacy, pharmacokinetics, and pharmacodynamics.

In this video, Dr. Bose discusses the rationale behind the study and its design, the safety and efficacy findings, and what he sees as the next steps.

Post Tags:MFASCO23
Editorial Board